Table 3.
The association between TFR2 genotypes and the risk of NAFLD
| Genotype | Controls [n (%)] | NAFLD cases [n (%)] | Propensity score matching |
Inverse probability of treatment weighting |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| OR1 (95% CI) | P 1 | OR2 (95% CI) | P 2 | OR1 (95% CI) | P 1 | OR2 (95% CI) | P 2 | |||
| rs10247962 | ||||||||||
| AA | 621 (81.7) | 652 (84.5) | 1 (reference) | – | 1 (reference) | – | 1 (reference) | – | 1 (reference) | – |
| GA + GG | 139 (18.3) | 120 (15.5) | 0.786 (0.590–1.046) | 0.098 | 0.859 (0.608–1.214) | 0.389 | 0.786 (0.650–0.950) | 0.013 | 0.839 (0.667–1.056) | 0.135 |
| rs1052897 | ||||||||||
| TT | 630 (82.2) | 655 (84.8) | 1 (reference) | – | 1 (reference) | – | 1 (reference) | – | 1 (reference) | – |
| TA + AA | 136 (17.8) | 117 (15.2) | 0.805 (0.603–1.075) | 0.142 | 0.862 (0.608–1.223) | 0.406 | 0.796 (0.657–0.964) | 0.019 | 0.840 (0.666–1.059) | 0.140 |
| rs2075672 | ||||||||||
| GG | 509 (66.4) | 501 (64.9) | 1 (reference) | – | 1 (reference) | – | 1 (reference) | – | 1 (reference) | – |
| GA + AA | 257 (33.6) | 271 (35.1) | 1.043 (0.834–1.305) | 0.713 | 0.939 (0.715–1.233) | 0.650 | 1.023 (0.882–1.187) | 0.763 | 0.939 (0.783–1.125) | 0.494 |
| rs3757859 | ||||||||||
| AA | 625 (81.7) | 643 (83.3) | 1 (reference) | – | 1 (reference) | – | 1 (reference) | – | 1 (reference) | – |
| CA + CC | 140 (18.3) | 129 (16.7) | 0.883 (0.666–1.170) | 0.385 | 0.954 (0.679–1.341) | 0.787 | 0.864 (0.717–1.041) | 0.124 | 0.918 (0.733–1.151) | 0.458 |
| rs4434553 | ||||||||||
| AA | 601 (78.9) | 649 (84.1) | 1 (reference) | – | 1 (reference) | – | 1 (reference) | – | 1 (reference) | – |
| GA + GG | 161 (21.1) | 123 (15.9) | 0.702 (0.533–0.924) | 0.012 | 0.625 (0.447–0.874) | 0.006 | 0.701 (0.584–0.843) | <0.001 | 0.630 (0.504–0.788) | <0.001 |
OR1 adjusted for age and sex.
OR2 adjusted for age, sex, body mass index, hypertension, diabetes, serum total triglyceride, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, alanine aminotransferase, aspartate aminotransferase, and the polymorphisms in the HFE2 gene.
NAFLD, non-alcoholic fatty liver disease; OR, odds ratio; CI, confidence interval.